Expedited Regulatory Pathways

Expedited regulatory pathways offer sponsors the opportunity to bring promising therapies to patients faster, but navigating these routes requires strategic planning, early engagement, and a clear understanding of regulatory expectations.

Whether you’re considering Fast Track, Breakthrough Therapy, Priority Review, or Accelerated Approval, success depends on aligning your development programme with the right evidence, endpoints, and submission strategy.

When Should You Apply for Fast Track?

Sponsors can request Fast Track designation as early as the initial IND submission, provided there is strong nonclinical data supporting the programme and the product is intended to treat a serious condition with unmet medical need. The FDA welcomes Fast Track applications based on nonclinical evidence, such as activity in animal models, mechanistic rationale, or pharmacologic data. Early engagement with the agency increases the likelihood of shaping endpoints, data strategy, and CMC plans to support accelerated approval.

Navigating Expedited Pathways

From Fast Track and Breakthrough Therapy to Accelerated Approval and PRIME, we help sponsors determine eligibility, prepare robust requests, and engage effectively with global health authorities to bring critical therapies to patients sooner.

How MMS Services Can Help with Expedited Pathways

Real-World Impact

A Practical Guide to Expedited Regulatory Pathways

Let’s Talk

Need immediate support or planning for future capacity?

About MMS

MMS is an award-winning, data-focused CRO with 18+ years of experience supporting pharmaceutical and biotech companies. Our medical writing experts bring deep domain knowledge, strong communication skills, and a drive to deliver from day one.